BACKGROUND: Very few studies have focused on fat redistribution induced by corticosteroids. OBJECTIVE: To establish the incidence and risk factors of facial ("moon face") and cervical ("buffalo hump") lipodystrophy due to long-term (> or =3 months), high dosage (>or =20 mg/d) systemic corticosteroid therapy. METHODS: Between June 2003 and May 2005 we conducted a prospective study in two French tertiary centers. All consecutive patients starting long-term systemic corticosteroid therapy at an initial daily dosage of 20 mg or more were enrolled in this study. Three investigators assessed the development of facial and cervical corticosteroid-induced lipodystrophy (CIL) from standardized photographs. Demographic, clinical, and nutritional data were examined to assess risk factors of CIL. RESULTS: Eighty-eight patients were enrolled (women: 75%, mean age: 57.4 +/- 17.9 years, mean baseline dosage of prednisone: 56 +/- 15 mg/d). The cumulative incidence rate of CIL at months 3 and 12 was 61% +/- 8% and 69% +/- 9%, respectively. In multivariate analyses the risk of CIL at the third month was higher in women (odds ratio [OR]: 10.87 [2.43-58.82]), in subjects younger than 50 years of age (OR: 11.11 [2.19-37.89]), in subjects with a high initial body mass index (OR: 1.56 [1.21-2.03] per increment of 1 kg/m2) and in subjects with high energy intake (OR: 6.11 [1.35-27.75] when higher than 30 kcal/d/kg). LIMITATIONS: Photographic analysis is not a conventional method for the diagnosis of CIL. CONCLUSION: CIL frequently occurs, especially in overweight subjects and in women, who are also at higher risk to develop other forms of lipodystrophies.
BACKGROUND: Very few studies have focused on fat redistribution induced by corticosteroids. OBJECTIVE: To establish the incidence and risk factors of facial ("moon face") and cervical ("buffalo hump") lipodystrophy due to long-term (> or =3 months), high dosage (>or =20 mg/d) systemic corticosteroid therapy. METHODS: Between June 2003 and May 2005 we conducted a prospective study in two French tertiary centers. All consecutive patients starting long-term systemic corticosteroid therapy at an initial daily dosage of 20 mg or more were enrolled in this study. Three investigators assessed the development of facial and cervical corticosteroid-induced lipodystrophy (CIL) from standardized photographs. Demographic, clinical, and nutritional data were examined to assess risk factors of CIL. RESULTS: Eighty-eight patients were enrolled (women: 75%, mean age: 57.4 +/- 17.9 years, mean baseline dosage of prednisone: 56 +/- 15 mg/d). The cumulative incidence rate of CIL at months 3 and 12 was 61% +/- 8% and 69% +/- 9%, respectively. In multivariate analyses the risk of CIL at the third month was higher in women (odds ratio [OR]: 10.87 [2.43-58.82]), in subjects younger than 50 years of age (OR: 11.11 [2.19-37.89]), in subjects with a high initial body mass index (OR: 1.56 [1.21-2.03] per increment of 1 kg/m2) and in subjects with high energy intake (OR: 6.11 [1.35-27.75] when higher than 30 kcal/d/kg). LIMITATIONS: Photographic analysis is not a conventional method for the diagnosis of CIL. CONCLUSION: CIL frequently occurs, especially in overweight subjects and in women, who are also at higher risk to develop other forms of lipodystrophies.
Authors: Gabriel P Esteves; Bruna Caruso Mazzolani; Fabiana Infante Smaira; Elizabeth Silva Mendes; Gabriela Guimarães de Oliveira; Hamilton Roschel; Bruno Gualano; Rosa Maria R Pereira; Eimear Dolan Journal: Rheumatol Adv Pract Date: 2022-04-21
Authors: Dora Liu; Alexandra Ahmet; Leanne Ward; Preetha Krishnamoorthy; Efrem D Mandelcorn; Richard Leigh; Jacques P Brown; Albert Cohen; Harold Kim Journal: Allergy Asthma Clin Immunol Date: 2013-08-15 Impact factor: 3.406
Authors: Lea Daniello; Mariam Elshiaty; Farastuk Bozorgmehr; Jonas Kuon; Daniel Kazdal; Hannah Schindler; Rajiv Shah; Anna-Lena Volckmar; Fabienne Lusky; Leonore Diekmann; Stephan Liersch; Martin Faehling; Thomas Muley; Mark Kriegsmann; Karolina Benesova; Albrecht Stenzinger; Michael Thomas; Petros Christopoulos Journal: Front Oncol Date: 2021-06-29 Impact factor: 6.244